C. difficile Toxin B

If you have sudden, persistent diarrhea after taking antibiotics, after a hospital stay, or with no obvious explanation, one of the first things worth ruling in or out is a C. difficile infection. This stool test looks for the genetic fingerprint of the toxin that makes this infection dangerous, and it gives an answer fast.

A negative result is reassuring and largely takes toxigenic C. difficile off the table. A positive result is more nuanced. It tells you the bacterium is there with the machinery to cause harm, but it does not by itself prove active disease. That distinction shapes everything that follows.

What This Test Actually Detects

This is a stool test that uses PCR (polymerase chain reaction, a technique that finds and copies specific pieces of genetic material) to look for the tcdB gene. That gene codes for toxin B, the main weapon C. difficile uses to damage the lining of your colon. Studies in human intestine show that toxin B causes cell injury, increased mucosal permeability, recruitment of immune cells called neutrophils, and inflammation, which is what produces the diarrhea and colitis people experience.

The key nuance: PCR detects the gene, not the toxin protein itself. A positive PCR means a toxigenic strain is present in your gut. It does not directly measure whether the bacteria are actively producing toxin in amounts large enough to damage your colon right now.

Why a Fast, Sensitive Answer Matters

C. difficile infection (CDI) is one of the most common causes of healthcare-associated diarrhea and ranges from mild loose stools to pseudomembranous colitis (severe colon inflammation with patchy plaques), toxic megacolon (a dangerously swollen colon), and in severe cases death. In recent cohorts, all-cause in-hospital mortality among CDI patients runs around 11 to 13 percent, with CDI-attributable mortality much lower, while specific high-risk subgroups such as ICU patients with hypervirulent strains can have substantially higher rates. Getting the diagnosis right quickly lets you start treatment if it is needed and avoid unnecessary antibiotics if it is not.

Across studies, stool tcdB PCR consistently outperforms older toxin immunoassays on sensitivity. In a 600-sample evaluation, PCR detected 92.2 percent of cases compared with the cytotoxin assay and 88.5 percent compared with cytotoxigenic culture, with specificities of 94.0 and 95.4 percent. In a 400-sample study, PCR sensitivity against toxigenic culture was 83.6 percent versus 67.2 percent for the cell cytotoxin assay. A multicenter study of 2,461 specimens showed 85.0 percent sensitivity and 97.2 percent specificity. More recent pooled estimates from a 2025 review put NAAT sensitivity at around 96 percent and specificity at around 94 percent, somewhat higher than the older individual-study figures.

The Strength of a Negative Result

The single most useful feature of stool tcdB PCR is how confidently a negative result rules out toxigenic C. difficile. In one hospital evaluation, sensitivity reached 100 percent and specificity 99.2 percent against toxigenic culture. Other studies report negative predictive values of 98.8 percent against the cytotoxin assay and 97.1 percent against toxigenic culture. Guideline reviews put the overall negative predictive value of NAAT at roughly 99 percent.

What this means for you: if you have diarrhea and your stool tcdB PCR is negative, C. difficile is very unlikely to be the cause. That clears the field for your clinician to look at other explanations and avoid empiric C. difficile treatment.

Why a Positive Result Is More Complicated

A positive PCR proves you carry a toxigenic strain. It does not prove that strain is causing your symptoms. People can carry C. difficile without disease. This is called asymptomatic colonization, and it is common in hospitalized patients and long-term care residents.

When researchers switched a hospital surveillance system from a multistep algorithm to PCR alone, reported CDI incidence rose by 52 percent. The PCR-only cases were far less likely to develop complications than cases positive by both PCR and a toxin assay (3 percent versus 39 percent). After PCR implementation in another hospital, the percentage of patients with positive results increased by more than 50 percent without a matching increase in true disease.

The PCR-Positive, Toxin-Negative Pattern

In one cohort of 190 PCR-positive patients, 43.7 percent were toxin EIA-negative. The toxin-negative patients had less leukocytosis, an elevated white blood cell count (11.0 percent versus 35.4 percent). Among 54 toxin-negative patients who were not treated for CDI, only three were later diagnosed with CDI, and none developed complications.

In a larger prospective study, virtually all CDI-related complications and deaths occurred in toxin-positive patients. Patients who were PCR-positive but toxin-negative had outcomes comparable to patients with no C. difficile detected by either method. Toxin-negative cases also had less prior high-risk antibiotic exposure and shorter hospital stays.

This is the apparent paradox most worth understanding: a positive PCR can be a real signal of disease or a real signal of harmless carriage, and the difference often hinges on whether free toxin is also present and whether you have classic symptoms like three or more unformed stools per day.

Reconciling the Two Pictures

PCR positivity and clinical CDI are not the same thing. PCR answers a microbiological question: do you carry a toxigenic strain? Active CDI is a clinical syndrome that requires both the organism and toxin-driven injury to your gut, expressed as diarrhea. The two questions overlap most of the time, but not always. That is why modern laboratories increasingly use multistep algorithms that combine PCR with a glutamate dehydrogenase (GDH) antigen test and a toxin enzyme immunoassay, rather than relying on PCR alone.

What Ct Values Add

PCR machines also produce a cycle threshold (Ct) value, which is essentially a measure of how much target DNA was in the sample. Lower Ct means more bacterial gene material, which tends to associate with more toxin and more severe disease.

In hospitalized adults, specimens with Ct of 25.0 or below were toxin-positive by the cell cytotoxicity neutralization assay in more than 90 percent of cases. In another study, samples that were PCR-positive, GDH-positive, and toxin-positive had a mean Ct of 23.3, compared with 33.5 for PCR-positive, GDH-negative, and toxin-negative samples. In pediatric patients, Ct cutoffs of 26.1 to 27.2 predicted free toxin with 100 percent sensitivity, and reporting Ct alongside PCR results reduced CDI treatment rates by 23 percent.

The honest limit: overlap is broad, and the negative predictive value of Ct for toxin status did not exceed 80 percent regardless of cutoff chosen. Ct is a useful clue, not a standalone verdict.

Disease Severity and Hypervirulent Strains

Some C. difficile strains are more aggressive. Ribotype 027 carries a tcdC mutation that was initially proposed to drive hyper-production of toxins A and B, although subsequent studies have produced conflicting results and the link between tcdC genotype and toxin production is no longer considered settled. What is more consistent is the clinical signal: in adjusted analyses, ribotype 027 roughly doubled the odds of mortality from CDI (about 2x more likely, odds ratio 2.02) and increased the odds of severe disease (about 1.7x more likely, odds ratio 1.73). Some PCR platforms can detect markers associated with these hypervirulent strains, adding information that toxin immunoassays cannot provide.

Patients with detectable stool toxin also tend to fare worse: in one study, they had higher disease severity scores (35.4 percent versus 23 percent) and higher recurrence rates (14.6 percent versus 5.9 percent) than toxin-negative patients.

When Results Can Be Misleading

Several factors can shift the interpretation of a single PCR result, and most of them have nothing to do with how the assay is performed.

• Asymptomatic colonization: in one Dutch admission screening study, about 3 percent of asymptomatic adults carried toxigenic C. difficile, while a broader pooled estimate across studies puts hospital admission colonization closer to 8 percent. Either way, a positive PCR in someone without diarrhea may simply reflect carriage.
• Recent laxative use: older guidance discouraged testing within 48 hours of laxative use, but more recent work suggests laxative exposure does not reliably exclude CDI and that withholding testing can delay diagnosis. Clinical judgment is needed when stool is loose primarily because of laxatives.
• Testing without symptoms that fit: guidelines recommend testing only patients with three or more unformed stools in 24 hours and no clear alternative cause. Testing outside those criteria inflates the chance of incidental positives that do not reflect true disease.
• Multiplex GI panels: broad stool panels that include C. difficile alongside other pathogens can produce incidental positives. In one analysis, 76 percent of patients with a positive C. difficile PCR on a multiplex panel were toxin-negative on follow-up testing, and 40 percent were negative for both toxin and GDH.

Antibiotic Exposure as the Main Risk Driver

Among medication-related factors, antibiotics stand out. In adults, exposure to high-risk antibiotics in the month before testing was independently associated with toxin-positive disease. Concurrent antibiotic use also tracked with worse CDI outcomes. The mechanism is well established: antibiotics disturb your gut microbiome and create the conditions in which C. difficile can expand and produce toxin.

This is important context for your test result. A positive PCR in someone who just finished a course of broad-spectrum antibiotics carries a different weight than the same result in someone with no recent exposures.

How This Fits Into a Workup

If you have new, unexplained diarrhea, stool tcdB PCR is one of the fastest and most sensitive ways to get an answer about C. difficile. If the result is negative, you and your clinician can confidently look elsewhere. If it is positive, the next questions are clinical: how many unformed stools per day, how long, any blood, any abdominal pain, fever, recent antibiotics, recent hospital stay, immune status.

In most modern workflows, a positive PCR triggers reflex testing with a toxin EIA or comparable assay. A PCR-positive, toxin-positive result strongly supports active CDI and treatment. A PCR-positive, toxin-negative result requires clinical judgment, and watchful waiting without empiric treatment is often appropriate in milder cases. A GI doctor or infectious disease specialist is the right person to involve if the picture is ambiguous or if symptoms recur.

Why Repeat Testing Is Usually Not Helpful

Unlike many biomarkers, this one is not meant for serial trending in healthy people. A single well-timed test in the setting of unexplained diarrhea answers most of the diagnostic question. Repeat testing during a confirmed active infection or as a test of cure after treatment is generally discouraged by guidelines, because PCR can remain positive for weeks after clinical recovery as long as colonization persists.

What matters more than retesting the same marker is whether your symptoms improve. If diarrhea resolves and you feel well, a lingering positive PCR usually reflects carriage, not failure of treatment. If symptoms come back days to weeks after treatment, that is a recurrence, and a fresh stool test paired with toxin testing is appropriate at that point.

What to Do With an Unexpected Positive

An unexpected positive PCR in someone with mild or no symptoms is best interpreted with help from a clinician. The pattern matters more than the single result. Things worth integrating into the decision include stool frequency and consistency, recent antibiotic use, hospitalization or long-term care exposure, white blood cell count, kidney function, and whether companion testing (toxin EIA, GDH, fecal calprotectin or lactoferrin as markers of intestinal inflammation) supports active disease.

If the result was incidental on a broad GI panel and you have no diarrhea, treatment is usually not indicated. If you have classic symptoms and a positive PCR, treatment decisions should be made promptly, and reflex toxin testing or an infectious disease consult can help clarify severity. Severe disease, signs of toxic megacolon, or recurrence usually warrant specialist involvement.